Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Publications

Transgenic mice for in vivo epigenome editing with CRISPR-based systems

Gemberling MP. et al, (2021), Nature Methods

Genome-Editing Strategies for Treating Human Retinal Degenerations

Quinn J. et al, (2021), Human Gene Therapy, 32, 247 - 259

The Potential Benefit of Expedited Development and Approval Programs in Precision Medicine.

Kantor A. and Haga SB., (2021), J Pers Med, 11

Is subretinal AAV gene replacement still the only viable treatment option for choroideremia?

Han RC. et al, (2021), Expert Opinion on Orphan Drugs, 9, 13 - 24

CRISPR genome engineering for retinal diseases

Kantor A. et al, (2021), Progress in Molecular Biology and Translational Science

CRISPR-Cas9 DNA Base-Editing and Prime-Editing.

Kantor A. et al, (2020), Int J Mol Sci, 21

Comparison of Cas9 Orthologues for Gene Suppression Activity

Kantor A. et al, (2020), MOLECULAR THERAPY, 28, 103 - 104

Horizon Scan Of Clinical Laboratories Offering Pharmacogenetic Testing

Haga SB. and Kantor A., (2018), Health Affairs, 37, 717 - 723

Include forthcoming?